跳至主要内容
临床试验/NCT01125306
NCT01125306Unknown4 期

Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom

Meir Medical Center2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2009年6月1日最近更新:
适应症

试验速览

阶段
4 期
入组人数
50
试验地点
2
主要终点
Consumption of Xalatan/Xalacom bottles per year per patient.

研究概览

简要总结

Xal-Ease is a novel Pfizer-Pharmacia device aimed to significantly facilitate the Xalatan/Xalacom instillation and to avoid loss of Xalatan/Xalacom eye drops due to incorrect instillation.

Patients on Xalatan/Xalacom who have consumed more than one bottle per month within a year according to consumption data drawn from the Clalit Health Services database, will use the Xal-Ease device for a year. The device is expected to reduce consumption of bottles and result in saving money for both patients and medical care providers.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with glaucoma or hypertension treated with Xalatan/Xalacom who have consumed more than one bottle per month within a year prior to initiation of the study.

排除标准

  • Patients younger than 18 years,
  • Patients with severe manual disabilities,
  • Patients with impaired cognition and mentality.

结局指标

主要结局

Consumption of Xalatan/Xalacom bottles per year per patient.

时间窗: 12 months.

次要结局

  • Evaluating cost of Xalatan/Xalacom eye drops use per year with Xal-Ease(12 months)
  • Characterizing the optimal conditions for proper usage of the Xal-Ease device(12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验